RemeGen Co., Ltd.

Languages

中文简体中文繁體 English

122020.11

Announcements and Notices - [Other - Business Update] VOLUNTARY ANNOUNCEMENT - DISITAMAB VEDOTIN INVESTIGATIONAL NEW DRUG (IND) APPLICATION APPROVAL AND FAST TRACK DESIGNATION IN THE UNITED STATES
062020.11

Announcements and Notices ‐ [Allotment Results] ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS
062020.11

Constitutional Documents - ARTICLES OF ASSOCIATION
062020.11

Announcements and Notices – [Terms of Reference of the Audit Committee] TERMS OF REFERENCE OF THE AUDIT COMMITTEE UNDER THE BOARD OF THE COMPANY
062020.11

Announcements and Notices – [Terms of Reference of the Nomination Committee] TERMS OF REFERENCE OF THE NOMINATION COMMITTEE UNDER THE BOARD OF THE COMPANY
062020.11

Announcements and Notices – [Terms of Reference of the Remuneration Committee] TERMS OF REFERENCE OF THE REMUNERATION AND APPRAISAL COMMITTEE UNDER THE BOARD OF THE COMPANY
062020.11

Announcements and Notices – [List of Directors and their Role and Function] LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
062020.11

PROCEDURES FOR SHAREHOLDERS TO NOMINATE AN INDIVIDUAL AS A DIRECTOR OR A SUPERVISOR OF THE COMPANY
062020.11

SHAREHOLDERS’ COMMUNICATION POLICY
062020.11

BOARD DIVERSITY POLICY

1 / 2

Jump To

1 / 1

Jump To

Telephone：0535-6113681
Email：zqb@remegen.cn

58 Beijing Middle Road, Yantai Shandong, China.
（+86）535-6113511
rcsw@remegen.cn

Company Wechat

Terms of Use Privacy Policy Media Resources

© All Right Reserved . ICP：鲁ICP备11031710号-1